Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine whether alternating courses of cyclophosphamide,
doxorubicin, vincristine, prednisone/dexamethasone, cytarabine, cisplatin (CHOP/DHAP) plus
rituximab followed by total body irradiation [TBI]/high dose cytarabine
[ARA-C]/melphalan-peripheral blood stem cell transplantation (TAM-PBSCT) can improve the time
to treatment failure compared to CHOP plus rituximab followed by standard PBSCT
(dexamethasone, carmustine, cytarabine, etoposide, and melphalan [Dexa-BEAM]/TBI/high dose
cyclophosphamide) in patients with untreated mantle cell lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
European Mantle Cell Lymphoma Network
Collaborators:
German Low Grade Lymphoma Study Group Lymphoma Study Association